Avinger, Inc. announced that John B. Simpson, MD, founder and Executive Chairman of Avinger, will be leaving the Company to pursue other opportunities. Concurrent with Dr. Simpson’s departure, James G. Cullen has been appointed non-executive Chairman of the Board. Mr. Cullen has been on Avinger’s Board of Directors since December 2014 and has been its Lead Independent Director since January 2015. He served as a director of Johnson & Johnson from 1995 until 2015, and was Presiding Director of the Johnson & Johnson board from 2003 to 2012. Mr. Cullen currently serves as a director of Agilent Technologies and Keysight Technologies, an electronic measurement spin-off from Agilent. He served as Agilent’s non-executive Chairman of the Board from 2005 until March 2017.
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).